Transgene SA (FRA:TGNA)

€ 1.07 0.02 (1.9%) Market Cap: 111.95 Mil Enterprise Value: 97.54 Mil PE Ratio: 0 PB Ratio: 7.10 GF Score: 32/100

Full Year 2023 Transgene SA Earnings Call Transcript
Mar 27, 2024

€1.08 (-0.55%)

Earnings
Half Year 2023 Transgene SA Earnings Call Transcript
Sep 20, 2023

€1.81 (+1.80%)

Earnings
Transgene SA Conference Call Transcript
May 05, 2023
Full Year 2022 Transgene SA Earnings Call Transcript
Mar 16, 2023

€1.91 (-1.55%)

Earnings
Transgene SA Interim Analysis of TG4001 Phase II Trial Call Transcript
Nov 02, 2022
Transgene SA R&D Day Transcript
Sep 27, 2022
Q2 2022 Transgene SA Earnings Call Transcript
Sep 07, 2022

€2.06 (+0.49%)

Earnings
Q4 2021 Transgene SA Earnings Call Transcript
Mar 16, 2022

€2.22 (+6.47%)

Earnings
Transgene SA Corporate Call Transcript
Dec 15, 2021
Transgene SA TG4050 Phase I Studies Results Webcast Transcript
Nov 23, 2021
Q2 2021 Transgene SA Earnings Call Transcript
Sep 22, 2021

€2.41 (+1.26%)

Earnings
Transgene SA Presents Results From the Phase 1b/2 trial of TG4001 in Combination with Avelumab Conference Call Transcript
Nov 12, 2020
Transgene SA Results from Clinical Study of TG4001 in Combination with Avelumab Conference Call Transcript
Jul 22, 2020
Q4 2019 Transgene SA Earnings Call Transcript
Mar 11, 2020

€1.23 (+6.59%)

Earnings

Transgene SA Interim Analysis of TG4001 Phase II Trial Call Transcript

Nov 02, 2022 / 05:00PM GMT

Release Date Price: €1.83

Transcript

Operator

Good day, and welcome to the positive interim analysis results of Phase II trial evaluating TG4001 plus avelumab conference call. At this time, I would like to turn the conference over to Madam Lucie Larguier. Please go ahead, ma'am.

Lucie Larguier

Transgene SA - Director of Corporate Communications & IR

Thank you, Nash, and hello, everyone. Thanks very much for joining this call at such short notice. The reason for the call, as you are aware, is the press release we issued today on TG4001 to communicate an exciting piece of news that we believe supports the value that our virus-based technologies can bring to the patients.

During our call today, we have Hedi Ben Brahim, CEO; and Maud Brandely, Chief Medical Officer; who will discuss the positive interim analysis results that we obtained in our Phase II trial, evaluating TG4001 plus avelumab versus avelumab alone in patients with HPV-positive anogenital cancers. The presentation will be followed by a Q&A session. (Operator Instructions) You can find the slide on the website, too. I'd like to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.